The Rheumatologist
COVID-19 News
You are here: Home / Articles / Optical Workings: Specialists Must Communicate to Treat Eye Disease

Optical Workings: Specialists Must Communicate to Treat Eye Disease

• By

Richard Quinn is a freelance writer in New Jersey.

References

ADVERTISEMENT
SCROLL TO CONTINUE
  1. AbbVie Inc. News release: AbbVie’s HUMIRA (adalimumab) receives U.S. Food and Drug Administration approval to treat adults with non-infectious intermediate, posterior and panuveitis. 2016 Jun 30.
  2. AbbVie Inc. News release: AbbVie receives orphan drug designation for Humira (adalimumab) from the U.S. Food and Drug Administration for the investigational treatment of certain forms of non-infectious uveitis. 2014 May 20.

ACR/ARP Annual Meeting

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Annual Meeting site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »